9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends NMTR vs. BPTH, TNFA, OGEN, ATXI, CELZ, FRTX, CPHI, ENVB, UPXI, and THARShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Bio-Path (BPTH), TNF Pharmaceuticals (TNFA), Oragenics (OGEN), Avenue Therapeutics (ATXI), Creative Medical Technology (CELZ), Fresh Tracks Therapeutics (FRTX), China Pharma (CPHI), Enveric Biosciences (ENVB), Upexi (UPXI), and Tharimmune (THAR). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Bio-Path TNF Pharmaceuticals Oragenics Avenue Therapeutics Creative Medical Technology Fresh Tracks Therapeutics China Pharma Enveric Biosciences Upexi Tharimmune Bio-Path (NASDAQ:BPTH) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings. Do analysts recommend BPTH or NMTR? Bio-Path currently has a consensus target price of $20.00, suggesting a potential upside of 2,274.45%. Given Bio-Path's stronger consensus rating and higher possible upside, research analysts plainly believe Bio-Path is more favorable than 9 Meters Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.009 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in BPTH or NMTR? Bio-Path received 245 more outperform votes than 9 Meters Biopharma when rated by MarketBeat users. However, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 53.82% of users gave Bio-Path an outperform vote. CompanyUnderperformOutperformBio-PathOutperform Votes28253.82% Underperform Votes24246.18% 9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% Which has stronger earnings & valuation, BPTH or NMTR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/A9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Does the media refer more to BPTH or NMTR? In the previous week, Bio-Path had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Bio-Path and 0 mentions for 9 Meters Biopharma. Bio-Path's average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score. Company Overall Sentiment Bio-Path Neutral 9 Meters Biopharma Neutral Do insiders & institutionals believe in BPTH or NMTR? 5.7% of Bio-Path shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is BPTH or NMTR more profitable? 9 Meters Biopharma's return on equity of -584.97% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% 9 Meters Biopharma N/A -584.97%-159.45% Which has more risk and volatility, BPTH or NMTR? Bio-Path has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. SummaryBio-Path and 9 Meters Biopharma tied by winning 6 of the 12 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$177.42M$5.39B$9.13BDividend YieldN/A3.64%5.37%4.00%P/E Ratio-0.02131.1588.8317.53Price / SalesN/A19,225.091,284.8380.47Price / CashN/A13.0136.6032.90Price / BookN/A9.234.964.69Net Income-$43.77M-$20.89M$117.89M$224.57M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220BPTHBio-Path1.4865 of 5 stars$0.93-1.7%$20.00+2,041.1%-89.9%$4.02MN/A0.0010Analyst ForecastNews CoverageTNFATNF PharmaceuticalsN/A$1.45+14.6%N/AN/A$4.00MN/A0.006Positive NewsHigh Trading VolumeOGENOragenicsN/A$0.33-5.2%N/AN/A$3.97M$40,000.00-0.055News CoverageATXIAvenue Therapeutics2.9599 of 5 stars$1.90+4.9%N/A-82.4%$3.90MN/A0.104Positive NewsHigh Trading VolumeCELZCreative Medical TechnologyN/A$2.23+2.8%N/A-46.3%$3.90M$11,000.00-0.595Positive NewsGap UpFRTXFresh Tracks TherapeuticsN/A$0.65-8.6%N/A-32.7%$3.88M$10.06M-0.4620Gap DownCPHIChina PharmaN/A$0.20-8.5%N/A-54.8%$3.87M$5.54M0.00231News CoverageGap DownENVBEnveric Biosciences3.1017 of 5 stars$0.38-6.7%$10.00+2,565.2%-67.5%$3.82MN/A-0.1520Positive NewsGap DownUPXIUpexi2.4408 of 5 stars$3.66-4.9%$25.00+583.1%-85.5%$3.81M$22.08M0.00130Positive NewsGap DownTHARTharimmune2.946 of 5 stars$1.93-5.9%$17.00+780.8%-65.5%$3.73MN/A0.002Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies BPTH Alternatives TNFA Alternatives OGEN Alternatives ATXI Alternatives CELZ Alternatives FRTX Alternatives CPHI Alternatives ENVB Alternatives UPXI Alternatives THAR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NMTR) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
